News

Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Press Release 03.2019: Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.

Press Release 02.2019: Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company’s clinical trial program.

Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.

Press Release 07.2018. Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).

Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.

Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.

Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.

Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action

Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Press Release 06.2017

Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.

Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company

Press Release 03.2017: Financing will support development of Radspherin®, a novel radiotherapeutic treatment for peritoneal carcinomatosis

Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.

Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.

The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific

The extraordinary General Assembly of Oncoinvent convened at July 28th unanimously decided to elect Ludvik Sandnes and Jónas Einarsson as new members of the Board of Directors.

Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.